Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results

August 18, 2026 9:20 AM

Benchmark analyst Robert Wasserman reiterated a Speculative Buy rating and $6.00 price target on Nephros (NASDAQ: NEPH).The analyst commented, "Nephros ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found